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Abstract
Background: Heat shock protein (hsp) 60 that provides ‘‘danger signal’’ binds to the surface of resting endothelial cells (EC)
but its receptor has not yet been characterized. In mitochondria, hsp60 specifically associates with adenosine triphosphate
(ATP) synthase. We therefore examined the possible interaction between hsp60 and ATP synthase on EC surface.
Methodology/Principal Findings: Using Far Western blot approach, co-immunoprecipitation studies and surface plasmon
resonance analyses, we demonstrated that hsp60 binds to the b-subunit of ATP synthase. As a cell surface-expressed
molecule, ATP synthase is potentially targeted by anti-EC-antibodies (AECAs) found in the sera of patients suffering
vasculitides. Based on enzyme-linked immunosorbent assay and Western blotting techniques with F1-ATP synthase as
substrate, we established the presence of anti-ATP synthase antibodies at higher frequency in patients with primary
vasculitides (group I) compared with secondary vasculitides (group II). Anti-ATP synthase reactivity from group I patients
was restricted to the b-subunit of ATP synthase, whereas those from group II was directed to the a-, b- and c-subunits. Cell
surface ATP synthase regulates intracellular pH (pHi). In low extracellular pH medium, we detected abnormal decreased of
EC pHi in the presence of anti-ATP synthase antibodies, irrespective of their fine reactivities. Interestingly, soluble hsp60
abrogated the anti-ATP synthase-induced pHi down-regulation.
Conclusions/Significance: Our results indicate that ATP synthase is targeted by AECAs on the surface of EC that induce
intracellular acidification. Such pathogenic effect in vasculitides can be modulated by hsp60 binding on ATP synthase which
preserves ATP synthase activity.
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Introduction
Adenosine triphosphate (ATP) synthase, or F0F1-ATPase,
produces and hydrolyzes ATP with proton translocation [1]. F0
operates as a proton channel with a rotation driving the F1 to
synthesize ATP, depending on the direction of rotation. F1
comprises 3 b-subunits assuming the catalytic activity modulated
by 3 a-subunits alternately ordered to form a cylinder, completed
by a c-subunit located at the center of the ab stalk, that constitutes
the key rotary element in the enzyme’s catalytic activity [2].
ATP synthase is resident in the inner mitochondrial membrane.
However,evidencesuggeststhatit isalso localized incellmembranes,
and translocate into the lipid rafts (LRs) of normal endothelial cells
(EC). Depending on cell type [3], cell surface ATP synthase triggers
hydrolysis or synthesis of ATP, modulates angiogenesis, cellular
immunity, cholesterol uptake and regulates intracellular pH (pHi).
Cell surface ATP synthase acts also to bind several ligands and
to control EC proliferation and differentiation [4]. For example,
angiostatin binds to ab-subunits, blocks ATP synthase activity
when EC are in a low extracellular pH (pHe) environment, and is
thus responsible for the inhibition of proton flux due to pH stress
[5]. The overall consequence is intracellular acidification that
induces EC death and inhibits neovascularisation [6]. By contrast,
apoliprotein A-I stimulates F1-ATPase activity following binding
and generates adenosine diphosphate that inhibits EC apoptosis
and promotes proliferation [7].
Alteration in ATP synthase function could therefore cause
significant damages to EC homeostasis. Furthermore, in the
mitochondria, heat shock protein (hsp)60 specifically associates
with ATP synthase [8], and ensures correct assembly of the
complex. Hsp60 is also present on EC surface [9]. Though several
ligands for different hsps have been listed [10], there is no clear
evidence about the one or those which can specifically bind to
hsp60 when found on the surface of EC. Thus, hsp60 binds to EC
irrespective of TLR2, TLR4, CD91 or CD14 expression [11,12].
Mitochondrial hsp70 has been identified as one ligand for hsp60
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uncharacterized in non-stressed conditions. Their intra-mitochon-
drial association suggests that translocation into extra-mitochon-
drial sites might facilitate ATP synthase and hsp60 interactions.
Interestingly, both ATP synthase and hsp60 can cause cytolysis
[4,14]. Hsp60 behaves as an antigenic target for antibodies (Abs),
such as anti-EC Abs (AECAs) [15] which are frequently associated
with vascular inflammation [16], and plays a role in promoting
and regulating autoimmunity [17,18]. Therefore, mitochondrial
proteins can generate immune responses contributing to damaged
EC. Their presence on the EC surface and the subsequent effects
of Ab binding might participate in the pathogenesis of vasculitides.
Depending on the site and the type of blood vessels affected,
clinical and pathological manifestations vary considerably. This
awareness has justified nomenclature of vasculitdies [19]. These
diseases may be autonomous and referred to as primary
vasculitides. They may affect small vessels in Wegener’s granulo-
matosis (WG), Churg-Strauss syndrome (CSS), microscopic
polyangiitis (MPA), medium vessels in polyarteritis nodosa (PAN)
or large vessels. These primary forms result from vasculitis which is
the triggering abnormality. Vasculitides may also be set against a
background of autoimmune diseases such as systemic lupus
erythematosus (SLE), primary Sjo ¨gren’s syndrome (pSS), or
rheumatoid arthritis (RA) and are then designated as secondary
vasculitides [20]. The current work was pursued to first
characterize possible interactions between ATP synthase and
hsp60 on the EC membrane, and second to evaluate the existence
of anti-ATP synthase Abs in vasculitides and their impact on
EC.
Results
I – ATP synthase is a receptor for hsp60
A minority of resting human umbilical vein EC (HUVEC)
bound to soluble hsp60 [15], suggesting that the ‘‘danger’’ signal
provided by hsp60 [21] might be detected by an as yet unidentified
receptor. To do so, we opted for a Far Western blot (WB)
approach. HUVEC membrane-enriched proteins were resolved
on 3 bidimensional gels. The first was stained with Coomassie blue
to verify the protein extraction procedure (Figure 1A, left panel).
Proteins from the second were blotted onto a PVDF membrane,
and probed with anti-hsp60 monoclonal Ab (mAb) to localize the
endogenous hsp60 (Figure 1A, middle panel). Proteins from the
third were incubated with recombinant hsp60 and probed with
anti-hsp60 mAb. This procedure identified 4 additional spots
relative to the second gel (Figure 1A, right panel). They were cut
out from the Coomassie blue-stained gel, analyzed by mass
spectroscopy and their amino acid sequence determined after
screening of the Swiss-Prot databank. Actin, ATP synthase b-
chain, prolyl-4-hydroxylase b-subunit and gp96 were identified
(Figure 1B). We focused on ATP synthase protein, and, to confirm
hsp60/ATP synthase b-subunit interaction, performed reverse co-
precipitation experiments. Immunoprecipitation with either mAbs
co-precipitated the other protein as shown by the 128-kDa
molecular weight (MW) complex (Figure 1C). The presence of
smears around this MW suggest the persistant interactions
between different ATP synthase subunits, and also that other
proteins may interact with ATP synthase or with hsp60.
Therefore, to demonstrate that ATP synthase could be the
receptor for hsp60, recombinant hsp60 was immobilized onto the
biosensor chip of a Biacore X system, ATP synthase injected into
the cell flow and their interaction followed in real time (Figure 1D).
Sensograms indicated that hsp60 interacts with ATP synthase as
shown by the curves that did not return to baseline.
Although ATP synthase is abundantly expressed in the
cytoplasm of permeabilized EC, a modest level of fluorescence
was found on the surface of nonpermeabilized EC by indirect
immunofluorescence (Figure 1E). This suggests that ATP synthase
could be accessible to hsp60 on the EC surface.
II – Detection of ATP synthase reactivity
We have previously demonstrated that among the EC surface-
expressed molecules [16] hsp60 could be a target for AECAs [15].
To assess whether ATP synthase, receptor for hsp60 was
recognized by AECAs as well, we screened AECA-positive sera
from different patient groups suffering vasculitides with an in-
house enzyme-linked immunosorbent assay (ELISA) using bovine
F1-ATP synthase as substrate. Sera were considered positive when
the optical density (OD) value was over than 0.410 (Figure 2A, left
panel). Thus, as shown in right panel of Figure 2A, 20% of
controls were reactive and there were more sera from group I
patients suffering primary vasculitides (36–73%) positive for ATP
synthase binding than from group II patients suffering secondary
vasculitides (5–28%, p,0.001).
Because a subgroup of controls displayed positivity, we asked
the question as to whether ATP synthase reactivity was similar to
that observed in sera from patients and whether those from group
I and II were different. To answer this question, reactivities were
evaluated by WB. Anti-ATP synthase Abs bound to 3 major bands
with a MW of 55, 51 and 30 kDa (Figure 2B), and 3 minor bands
of 40, 38 and 32 kDa, that were sequenced. The 3 major bands
were the a-, b- and c-subunits of F1-ATP synthase, and the 3
minor bands were degradation products of the b-subunit. Sera
reactivities were considered positive when the OD values after
densitometry analysis were over 3.9.10
5 AU, 4.5.10
5 AU and
3.8.10
5 AU for a-, b-, and c-subunit, respectively (Figure 2C, left
panels). Regarding overall reactivities, more than 13% of sera
from the controls were positive in the WB. Furthermore, more sera
from group I were positive (50–86%) than those from group II
(45–78%, p=0.005). In the controls, frequencies of positive sera
were 6.7, 10 and 6.7% for a-, b- and c-subunit, respectively.
(Figure 2C, right panels). Reactivity was strikingly homogeneous in
sera from group I patients since all were reactive only for the b-
subunit. In group II patients, percentages of positivity ranged from
5–15.6% for the a-subunit, 5.6–17.2% for the b-subunit and 18.7–
77.8% for the c-subunit.
We, next, assessed the latent multi-reactivity of positive anti-
ATP synthase sera. Positivity for the b-subunit in group I was not
associated with other reactivity (Figure 3), and the one positive for
the c-subunit was negative for the others. It is concluded that sera
from patients with primary vasculitides exhibited homogeneous
reactivity to F1-ATP synthase. By contrast, 1 control serum
positive for a-subunit (C24) was also positive for b-, and 1 (C2) was
positive for the c-subunit as well. One control was only positive for
the b-subunit (C7), and another 1 (C1) for the c-subunit. When
positive, reactivities of control sera for F1-ATP synthase appeared
heterogeneous. In group II patients, 7 SLE sera were only reactive
for the a-subunit (SLE1, 8, 36, 50, 51, 52 and 54), 2 (SLE15 and
SLE30) were positive for the a-subunit and also for the c-subunit,
and 1 (SLE4) for the a-subunit, the c-subunit and the b-subunit
too. Eleven SLE sera were positive for the b-subunit among which
9 had no other reactivities (SLE2, 28, 42, 56, 57, 58, 59, 61 and
63) and 1 (SLE23) was also positive for the c-subunit. Finally, 9 of
12 sera positive for the c-subunit displayed a single reactivity
(SLE9, 12, 18, 20, 22, 24, 27, 48 and 64). Reactivities of pSS
patients appeared to be less heterogeneous since all positive sera
reacted with the c-subunit, among which only 1 (pSS4) was also
positive for the a-subunit and one (pSS6) also positive for the b-
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PLoS ONE | www.plosone.org 2 February 2011 | Volume 6 | Issue 2 | e14654Figure 1. ATP synthase is a receptor for soluble hsp60. A- HUVEC membrane-enriched protein were electrophoresed on bidimensional gels.
Left panel: staining with Coomassie blue. Middle panel: WB with anti-hsp60 mAb. Right panel: WB with recombinant hsp60 revealed with anti-hsp60
mAb. B- Mass spectrometry data of proteins bound to hsp60. C- Hsp60 and ATP synthase were co-immunoprecipitated from membrane-enriched
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(RA10) reactive with the a-subunit. Two of them (RA9 and RA14)
were also positive for the b-subunit. We concluded that among
anti-ATP synthase reactive sera, those from patients with
secondary vasculitides presented the broadest multi-reactivity
pattern (p=0.04) for the F1-ATP synthase subunits (Table 1).
III – Modulation of ATP synthase function
We then asked the question as to whether anti-ATP synthase
Abs could alter the ATP synthase-dependent regulation of pHi [3].
EC were stained with 29,79-bis-carboxyethyl-5,6-carboxyfluores-
cein (BCECF), and pilot experiments elaborated by flow cytometry
to validate the protocol that measures emission intensities of
BCECF at 525nm and 640nm. To this end, EAhy926 EC line cells
were treated with nigericin and incubated in medium with
different pHe from 6.7 to 8. Nigericin is an ionophore that
exchanges K
+ and H
+ across cellular membranes [22]. pHi
measured in these conditions corresponds to pHe. Intracellular
525/640 ratios increased with pHe (Figure 4A) indicating that flow
cytometry analyses were efficient. Moreover, the ratio was left
stable without nigericin, demonstrating that nontreated EC
retained their ability to maintain constant pHi between pHe 6.7
to 8. Additionally, to evaluate ATP synthase function, EC were
pre-treated with piceatannol, an inhibitor of ATP synthase [23],
and incubated in an acidic pHe 6.7 medium. pHi decreased to
7.160.1 while it was maintained at 7.3860.11 (p=0.004) in
medium free from ATP synthase inhibitor (Figure 4B), demon-
strating the importance of ATP synthase activity in pHi regulation.
Interestingly, pre-treatment of EC with anti-ATP synthase mAb
also reduced pHi to 7.0860.07 (p=0.005). These results indicate
that anti-ATP synthase Abs can inhibit ATP synthase function. By
contrast, pHi remained stable at 7.5560.07 (p=0.6, Figure 4C)
and 7.760.09 (p=0.37, Figure 4D) when EC were incubated with
anti-ATP synthase mAb in neutral (pHe 7.4) or basic (pHe 8)
medium, respectively. These experiments demonstrate that anti-
ATP synthase mAb alters ATP synthase activity only in acidic
environment. This conclusion was confirmed by pre-treatment of
EC with oligomycin another inhibitor of ATP synthase [24]. pHi
decreased only when EC were incubated in acidic pHe medium.
Furthermore, no effects could be observed with anti-hsp Abs, with
sodium azide at the concentration found in anti-ATP synthase
mAb preparation, nor with DMSO (not shown).
Effect of anti-ATP synthase Abs from sera was therefore
evaluated with EC incubated at pHe 6.7 (Figure 5A). Sera from
controls, reactive or unreactive for ATP synthase, did not reduce
pHi which were maintained at 7.45–7.51. Nearly all sera positive
for ATP synthase from group I patients reduced pHi of EC
between 6.93 and 7.2. Some had no effect with pHi sustained at
7.46–7.48. ATP synthase positive sera from group II patients
displayed diverse effects. A striking down-regulation between
6.85–6.97 was observed with a subgroup of sera from SLE
patients, indicating a strong inhibition of ATP synthase function.
Another subgroup slightly diminished pHi between 7.23–7.48.
Sera from patients with pSS induced intermediate inhibition of
ATP synthase activity with pHi decreased between 7.08 and 7.22.
Finally, sera from RA patients were variable, from a strong
decrease of pHi to 7.05 to a minor reduction at 7.39. Overall,
these data demonstrate varied effects of anti-ATP synthase Abs
from sera on ATP synthase function.
To further elucidate this issue, we appraised specific ATP
synthase subunit reactivity. Positivity for a-, b- and/or c-subunits
were inspected in sera inducing or not down-regulation of pHi. As
shown in Figure 5A, effect on pHi regulation could not be
designated with particular ATP synthase reactivities. Thus, while
some b-reactive sera decreased pHi others had no effect. Similarly,
some a-reactive sera did not affect pHi whilst others reduced it.
Moreover, multireactivities did not appear as a decisive factor
either. These prompted us to assess Ab titres. The analysis did not
show a correlation between OD values for the ELISA and pHi
values of EC determined in the presence of sera (Figure 5B),
suggesting that effect on pHi was not related to Ab concentration.
Nevertheless, down-regulations of pHi were abrogated when sera
were depleted of their anti-ATP synthase reactivities by overnight
incubation in ATP synthase-coated microplates (Figure 5C). These
data confirm that effects of anti-ATP synthase positive sera on pHi
modulation are specifically due to ATP synthase recognition.
IV – Regulatory role for hsp60 in ATP synthase activity
Once hsp60 was shown to be a novel ligand for ATP synthase
on EC surface, we sought to evaluate its role on the function of
ATP synthase. Binding of recombinant hsp60 to EC cultured in
acidic pH 6.7 medium had no effect on pHi that was retained at
7.3860.07, compared with pHi 7.3560.11 of control EC
(p=0.76, Figure 5D). This data indicates that binding of soluble
hsp60 does not alter ATP synthase activity. However, reduction of
pHi to 7.1060.07 (p=0.03) following stimulation of EC with anti-
ATP synthase b-chain Ab was abrogated when EC were pre-
incubated with recombinant hsp60. Thus, pHi was up-regulated to
7.2960.06 (p=0.03). These results indicate that hsp60 preserved
EC from a decrease in pHi subsequent to the binding of anti-ATP
synthase Abs at least when they bind to the b chain.
Discussion
This study establishes specific interactions between ATP
synthase and hsp60 on the surface of EC, based on Far WB
associated with mass spectrometry. Because a single spot may
contained several proteins, mass spectrometry will detect the most
abundant species. We, therefore, decided to verify the specific
interactions using different approaches. Co-immunoprecipitation
and surface plasmon resonance analyses confirmed ATP synthase
and hsp60 interaction. We determined that soluble hsp60 interacts
with the 51 kDa b-subunit of ATP synthase on EC surface. In the
mitochondria, hsp60 associates with at least two proteins [8]. One
is the 55kDa a-subunit and the second is a 40kDa protein that has
not been identified but that could be a product of the b-subunit as
suggested herein in Figure 2B. These observations imply that a-
subunit and b-subunit of ATP synthase would be able to associate
with hsp60 in the mitochondria, whilst cell surface ATP synthase
binds hsp60 with its b-subunit only. We did not observe
association with the a-subunit. Whether differential conformation
of F1-ATP synthase between mitochondrial and cell surface
molecules might be responsible for this difference remains to be
protein extracts of EAhy926 cells with anti-ATP synthase and anti-hsp60mAbs, respectively. Proteins were analysed by WB using polyclonal anti-hsp60
or anti-ATP synthase Abs. MW markers are on the left. D- Increasing amounts of ATP synthase were passed over hsp60 immobilized onto a sensor
chip. Sensogram of each amount of analyte with substraction of non-specific binding represent resonance units. Specific binding is shown (D). E-
EAhy926 cells, permeabilized or not, were incubated with a primary anti-ATP synthase Ab revealed by FITC-conjugated anti-Ig Ab, and intracellular as
well as cell-surface expression of ATP synthase analyzed by fluorescence microscopy. Propidium iodide was used to visualize nuclei, and isotype
control staining performed as negative control.
doi:10.1371/journal.pone.0014654.g001
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PLoS ONE | www.plosone.org 4 February 2011 | Volume 6 | Issue 2 | e14654Figure 2. Reactivity of sera with ATP synthase. A- Optical densities (left panel) and percentages of positivity (right panel) of sera from patients
in ELISA with purified ATP synthase. Broken line depicts the cut off level for positivity (OD 0.410, representing the mean+2 SD of control values).
Group I corresponds to patients with primary vasculitides (WG, PAN, MPA and CSS) and group II to patients with secondary vasculitides associated
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chaperon to protect ATP synthase from degradation on EC
membranes. However, chaperon activity requires the presence of
ATP which is lacking in our in vitro experiments. This aspect is thus
unlikely to occur. Moreover, we can not exclude the possibility
that other chaperons such as mitochondrial hsp70 may also be
able to interact with ATP synthase. Furthermore, the fraction of
ATP synthase that co-localized with hsp60 into lipid rafts (not
shown) suggest that hsp60/ATP synthase interactions participate
also in signaling, and thereby influence ATP synthase-dependent
activation and proliferation of EC [25,26]. This is consistent with
other observations on extracellular ATP synthase in lipid rafts
[27].
The second part of our work focused for the first time on
determining the pattern of anti-ATP synthase reactivity in sera
from patients containing AECAs known to be potentially
pathogenic in vasculitides [28–30]. The frequencies of positivity
were higher in patients with primary vasculitides (group I) than in
those with secondary vasculitides (group II). The 3 major a-, b-
and c-subunits that constitute the F1 structure [2] were found
antigenic. Intriguingly, sera from patients with primary vasculit-
ides had a homogeneous pattern of Ab reactivity to the b-subunit
of ATP synthase. By contrast, Abs from secondary vasculitides
were multi-reactive. The most heterogeneous pattern was seen in
sera from SLE patients with mono-, bi- and tri-reactivities. RA
sera had only 2 different mono- and one bi-reactivity patterns,
while Abs in the sera of pSS were homogeneous with a striking
elevated frequency of mono-reactivity for the c-subunit and 2
minor bi-reactivities. Overall, there was possiblity that patients
with Abs directed to the b-subunit were those with active vasculitic
disease at the time they were sampled. However, further analysis
could not establish an influence of disease activity nor of
medication on the Ab pattern, and reactivity with the b-subunit
was not restricted to group I patients. The reasons for mono-
with autoimmune diseases (SLE, pSS, RA). B- Purified ATP synthase was subjected to electrophoresis and blotted with sera from patients and controls.
Representative results from controls, group I and group II patients are shown. MW markers are on the left. Result with anti-b-subunit mAb and
Coomassie blue (CB) staining are shown as controls. C- Densitometry measurement (left panels) and percentages (right panels) of sera activities
against a-, b- and c-ATP synthase subunits by Western blots. Broken lines show the cut off level for positivity (OD 3.9.10
5, 4.5.10
5 and 3.8.10
5 arbitrary
units, representing the mean+2 SD of control values for a-, b-, and c-subunit, respectively). WG=Wegener’s granulomatosis; PAN=polyarteritis
nodosa; MPA=microscopic polyangiitis; CSS=Churg-Strauss syndrome; SLE=systemic lupus erythematosus; pSS=primary Sjo ¨gren’s syndrome;
RA=rheumatoid arthritis.
doi:10.1371/journal.pone.0014654.g002
Figure 3. Multireactivity of anti-ATP synthase Ab positive sera. Sera from group I (WG, PAN, MPA, CSS), group II (SLE, pSS, RA) patients and
controls positive for the a-, b-, or c-subunit of ATP synthase were evaluated for their reactivity against all subunits. Densitometry measurements of
reactivity by Western blots are shown. Broken lines show the cut off level for positivities against a-subunit (3.9.10
5 AU), b-subunit (4.3.10
5 AU) and c-
subunit (3.9.10
5 AU), corresponding to the mean+2 SD of control values. WG=Wegener’s granulomatosis; PAN=polyarteritis nodosa;
MPA=microscopic polyangiitis; CSS=Churg-Strauss syndrome; SLE=systemic lupus erythematosus; pSS=primary Sjo ¨gren’s syndrome; RA=rheu-
matoid arthritis.
doi:10.1371/journal.pone.0014654.g003
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largely unknown.
Modulation of ATP synthase activity was addressed in the last
part of our experiments. The main function of cell surface ATP
synthase appears to act as proton transport [3]. Proton flux across
the membrane allows rotation of the c-subunit, which in turn,
induces modification of the a- and b-subunit conformation
required for ATP synthesis [1]. When incubated in acidic pHe
Table 1. ATP synthase multi-reactivities in sera from controls and from patients with primary and secondary vasculitides
associated systemic autoimmune diseases found positive by Western blotting*.
Frequencies (no) of anti-ATP synthase reactivity
a-subunit + 22+ 2 ++
b- subunit 2 + 2 ++2 +
c-subunit 22+ 2 +++
Control (n=4) 0 25.0 (1) 25.0 (1) 25.0 (1) 0 0 25.0 (1)
Primary vasculitides
WG (n=19) 0 100.0 (19) 0 0 0 0 0
CSS (n=9) 0 100.0 (9) 0 0 0 0 0
PAN (n=3) 0 66.6 (2) 33.3 (1) 0 0 0 0
MPA (n=8) 0 100.0 (8) 0 0 0 0 0
Secondary vasculitides
SLE (n=29) 27.6 (8) 31.1 (9) 31.1 (9) 0 3.4 (1) 3.4 (1) 3.4 (1)
pSS (n=14) 0 0 85.8 (12) 0 7.1 (1) 7.1 (1) 0
RA (n=9) 11.1 (1) 0 66.7 (6) 0 22.2 (2) 0 0
*ATP synthase reactivities to the 55 kDa a-subunit, the 51 kDa b-subunit and the 30 kDa c-subunit were determined by Western blotting.
doi:10.1371/journal.pone.0014654.t001
Figure 4. ATP synthase regulates intracellular pH. EAhy926 cells were labelled with BCECF, incubated with or without 40 mM nigericin in
medium at different extracellular pH (pHe), and analyzed by flow cytometry. Fluorescence emission ratio 525nm/640nm (green fluorescence/red
fluorescence) following BCECF excitation was calculated to determine calibration curves (A). BCECF-labelled EAhy926 cells were incubated either
alone (control), with 40 mM nigericin, 80 mM piceatannol, or 50 mg/ml anti-ATP synthase mAb in medium at pHe 6.7 (B), 7.4 (C), or 8 (D). Ratio 525/
640 was calculated and intracellular pH (pHi) determined with the calibration curves. Mean6SD of 3 experiments.
doi:10.1371/journal.pone.0014654.g004
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and helps EC to survive [4]. Therefore, decreased pHi of EC
observed in the presence of anti-ATP synthase Ab from patients
may result from different effects. Binding of Abs to the c-subunit
might block its rotation, whilst binding to the a-o rb-subunits may
alter their conformational changes. Consequently, Abs inhibit
ATP synthase activity and decrease pHi of EC. These observations
are consistent with others based on the use of polyclonal anti-b-
subunit Abs that produce intracellular acidification of EC
triggering cell death [5]. However, this interpretation is not in
line with other data [5], where any effect was observed with
polyclonal anti-c-subunit Abs. We suggest that inhibition of ATP
synthase activity is likely dependent on specific epitope recognition
rather than determined by a particular subunit binding. It is
noteworthy that anti-ATP synthase mAb 7H10 directed to the a-
subunit inhibits ATP synthase activity [5] whereas other anti-a-
subunit clones do not [31]. Conceivably, the absence of effects
observed with the positive control sera, and the differential
responses observed in group I compared with group II sera
(Figure 5A) might reflect disparate epitope bindings. Furthermore,
piceatannol and oligomycin, inhibitors of ATP synthase [23,24],
have different effect on intracellular acidification. When EC were
incubated in neutral or basic pHe, piceatannol still promoted
decreases of pHi. This might be due to its ability to inhibit
phosphorylation pathway [32]. Consequently, dephosphorylation
of NA
+/H
+ transporter would be responsible for pHi diminution
[33]. Whether some Abs may affect similarly ATP synthase
remains to be determined.
Of interesting note is that the effects of anti-ATP synthase Abs
depend on the pHe environment since no variations could be seen
in EC incubated in media with neutral or basic pHe. This raises
the possibility that anti-ATP synthase Abs, as recently suggested in
Alzheimer’s disease [34], may contribute to the pathogenicity of
renal tubular acidosis that can be observed in patients with
primary vasculitides [35] and in pSS patients with secondary
vasculitides [36], or in SLE patients developing interstitial
nephritis [37]. Furthermore, acidosis, considered as a hallmark
of tumor microenvironment [3], is associated with lymphoma in
patients with pSS [38]. Thus, among AECAs, anti-ATP synthase
Abs should be considered as pathogenic contributors of EC
deregulation. It is noteworthy that vasculitides represent hetero-
geneous inflammatory diseases that affect different ECs in arteries,
arterioles, capillaries, veinules and veins toward major body
regions [39]. Therefore, there are possibilities that in in vivo
Figure 5. Anti-ATP synthase auto-Abs modulate ATP synthase function. A- EAhy926 cells were labelled with BCECF, incubated in pH 6.7
medium with sera showing different reactivity patterns against a-, b-, and c-subunit of ATP synthase, and analyzed by flow cytometry. Intracellular pH
(pHi) was then calculated from calibration curves. B- Correlation between ATP synthase reactivity determined in ELISA and pHi of EAhy926 cells
incubated in the presence of sera in pH 6.7 medium. C- ATP synthase positive sera were depleted (open bars) or not (solid bars) of their ATP synthase
reactivity and incubated with BCECF-loaded EAhy926 cells in pH 6.7 medium. After flow cytometry analyses, pHi were determined using calibration
curves. ATP synthase positive (C24) and negative (C25) sera from healthy donors were used as controls. D- BCECF-loaded EAhy926 cells were
incubated with recombinant hsp60 before suspension in medium pH 6.7 in the presence of 50 mg/ml anti-ATP synthase mAb. After flow cytometry
analyses, pHi were determined using calibration curves. Mean6SD of 3 experiments. WG=Wegener’s granulomatosis; CSS=Churg-Strauss syndrome;
MPA=microscopic polyangiitis; SLE=systemic lupus erythematosus; pSS=primary Sjo ¨gren’s syndrome; RA=rheumatoid arthritis.
doi:10.1371/journal.pone.0014654.g005
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type of ECs to another.
In addition, binding of hsp60 to ATP synthase might compete
with Ab and inhibits the anti-b chain ATP synthase Ab-induced
pHi down-regulation (Figure 5D). This indicates that soluble
hsp60, whose level is elevated in vasculitides [21], may have
protective effects. It remains to determine whether the effective-
ness of the protective effect of hsp60 occurs regardless of the
specificity of the anti-ATP synthase Ab. Nevertheless, at low pHe
environments, this ‘‘danger’’ signal allows EC to maintain normal
pHi owing to the preservation of a functional ATP synthase, and
promotes cell survival. These effects may depend on the
environment. It has thus been suggested that expression of
hsp60 increases at sites predisposed to atherosclerotic lesions in
response to EC stress [40]. Furthermore, arteriosclerosis can be
induced or aggravated by hsp60 immunization [41,42] implying
that hsp60 can contribute to the development of cardiovascular
diseases [43].
In sum, we provide new insights into the pathogenicity of
AECAs in vasculitides. Recognition of cell surface ATP synthase at
low pHe microenvironment contributes to intracellular acidifica-
tion of EC known to induce cell death and the triggering of
inflammation. However, the concomitant presence of soluble
hsp60 might partly offset this deleterious response due to the
specific interaction with ATP synthase. Further investigations are
required to design therapeutic strategies derived from these
pathogenic mechanisms.
Materials and Methods
Ethics statement
Ethics approval was given by the Institutional Review Board of
the Brest University Hospital, of Lyon Hospital and of La Pitie ´
Salpe ´trie `re Hospital. Use of samples from WG, CSS, MPA and
PAN were approved by the Institutional Review Board of Lyon
Hospital and La Pitie ´ Salpe ´trie `re Hospital respectively, and those
from SLE, RA and pSS by that of the Brest University Hospital.
All participants gave their written informed consent to participate
in this study.
Cell cultures
HUVEC were prepared by digestion with 0.1% collagenase,
grown to confluence [11], and passaged twice in DMEM (Gibco)
with 10% fetal calf serum, 2mM glutamine and 100IU/mL
polymyxin B prior to use.
The EAhy926 EC were grown in DMEM supplemented with
10% fetal calf serum, 2mM glutamine, 100 mM hypoxanthine,
0.4 mM aminopterin, 16 mM thymidine and 50mg/L gentamycin.
Two-dimensional electrophoresis
HUVEC were detached from culture flasks with trypsin, washed
and resuspended in a homogenization buffer (1M sucrose, 100mM
Tris-Hcl, 100mM EDTA, 50mM MgCl2,1mM leupeptin, 1 mM
pepstatin, 1 mM aprotinin). After freezing-thawing cycles, sonica-
tion, and centrifugation, membrane-enriched protein fractions
were resuspended in solubilization buffer (4% CHAPS, 1% Triton
X-100), centrifuged at 10,000g, and protein concentration
determined using the Micro BCA protein assay kit (Pierce).
Protein extracts were resuspended in re-hydration buffer (4%
CHAPS, 1% Triton X-100, 7M urea, 2M thiourea, 0.48% 3–10
biolyte, 1% tributylphosphine), and loaded onto pH 3–10 or
pH 4–8 immobilized pH gradient strips (BioRad) for isoelectric
focusing. After passive re-hydration, proteins were focused with a
protean immunoelectrofocalisation cell (BioRad). Strips were then
incubated in equilibration solutions before subjected to 10% SDS-
PAGE. For the spot identifications, proteins of interest were cut
out from the Coomassie blue-stained gel, digested with trypsin,
desalted and deposited on 600 mm Scout MTP 384 AnchorChip
(Brucker Daltonics). Peptidic fingerprints were obtained by mass
spectroscopy analysis using the Ultraflex MALDI (Brucker
Daltonics). The threshold for positivity was scored at 78. The
detected peptide masses were then searched against Swiss-Prot
dabatase.
Co-immunoprecipitation
Cell surface proteins were cross-linked with 20 mg/ml bis(sulfo-
N-succinimidyl) for 20 min at 4uC. After addition of 1vol of 10mM
Tris, membrane-enriched fractions were obtained using a
modified solubilization buffer (50mM Tris, 1% Triton X-100,
150mM NaCl). Protein solutions were pre-cleared with protein G-
coated beads, and precipitated with polyclonal anti-hsp60 or anti-
ATP synthase Ab-coated protein G beads (Abcam). The proteins
were washed in modified solubilization buffer, and retained
proteins eluted with 0.1% Triton X-100 and 0.1M triethylamin,
pH 11.8 and resolved by WB.
Western and Far Western blotting
Proteins were transferred onto PVDF membranes and probed
with anti-hsp60 mAb (clone LK-1, Calbiochem) or anti-ATP
synthase mAb (clone 3D5, Abcam), amplified with biotinylated
anti-Ig Ab (Jackson), and developed with horseradish peroxydase
(HRP)-conjugated streptavidin (Amersham). For the Far WB
experiments, PVDF membranes were first incubated with 2 mg/ml
recombinant hsp60 (Sigma), and then probed with anti-hsp60
mAb before development.
Detection of cellular expression
HUVEC and EAhy926 cells were suspended in PBS, incubated
with anti-ATP synthase mAb and FITC-conjugated secondary
Abs, washed and analyzed in an Epics XL (Beckman Coulter) flow
cytometer. Cells stained with an isotype control Ab and the FITC-
conjugated Abs were enabled to set the level of positivity.
For indirect immunofluorescence staining, EC were cultured
onto 10-well slides until confluence. They were incubated with
anti-ATP synthase or isotype control mAb, and FITC-conjugated
secondary Ab and propidium iodide, fixed in paraformaldehyde,
and slides mounted in glycerol and examined with a TCS-NT
confocal microscope (Leica).
Surface plasmon resonance-based analysis
Surface plasmon resonance analyses were performed using the
Biacore X system from GE Healthcare (INSERM U613, Brest).
Due to the heterogeneity of the purified bovine ATP synthase
complex, recombinant hsp60 was immobilized onto a carbox-
ymethyldextran biosensor chip using amine coupling. Briefly, a
continuous flow of 5 ml/min was maintained over the sensor in
10mM HEPES, 150mM NaCl, 2mM EDTA. The matrix of the
chip was activated by a 7-min injection of 0.05M N-hydroxy-
succinimide with 0.3M N-ethyl-N-(3-diethylaminopropyl) carbo-
diimide, followed by a 6-min injection of recombinant hsp60 in
10mM sodium acetate, pH4.5. The procedure was completed by a
7-min exposure to ethanolamine hydrochloride to inactivate
residual esters. Density of immobilized hsp60 was ,10ng/mm
2.
Purified bovine ATP synthase was injected at a flow rate of 10 ml/
min over the immobilized recombinant hsp60 (Flow Cell 2). In
control experiments, another part of the same sensor was treated
as above but in the absence of recombinant hsp60 (Flow Cell 1).
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pulse of 50mM NaOH to dissociate the analyte from the ligand.
The final sensograms were calculated by substrating the signal of
the control (Flow Cell 1) from that of the test (Flow Cell 2), and
results expressed in resonance units.
Patients
Group I sera comprised primary systemic vasculitides: 22
patients with Wegener’s granulomatosis (WG), 14 with Churg-
Strauss syndrome (CSS), 6 with polyarteritis nodosa (PAN) and 10
with microscopic polyangiitis (MPA). Group II sera comprised
secondary systemic vasculitides associated with autoimmune
diseases: 64 patients with systemic lupus erythematosus (SLE), 18
with primary Sjo ¨grens’ syndrome (pSS) and 20 with rheumatoid
arthritis (RA). All patients are Caucasian and fulfilled the criteria
for their respective disease and the sera were selected based on
their positivity for AECAs [44]. Concurrently, sera from 30
laboratory staff volunteers were studied as controls. They were
matched for age and sex to the two groups of patients. Thus, there
were 3 women for 1 man, and their ages ranged from 23 to 66
years.
Measurement of ATP synthase reactivity
Anti-ATP synthase autoAbs were detected using an in-house
made ELISA [45]. Microtiter plates were sensitized with 0.5 mgo f
purified bovine ATP synthase at 5 mg/ml, blocked with PBS
containing 2% BSA, incubated with 100 mL of serum diluted 1:50
in 1% BSA and developed with alkaline phosphatase-conjugated
anti-human IgG (Zymed). Optical density (OD) of control wells
without ATP synthase were subtracted from the OD of ATP
synthase-coated wells. The mean+2 standard deviations (SDs) of
the OD values in negative control sera was taken as the threshold
for positivity.
Reactivity was also determined by WB to evaluate the
recognition of ATP synthase subunits. The protein complex was
subjected to 10% SDS-PAGE, transferred onto PVDF membranes
saturated with PBS containing 5% milk proteins, and probed with
sera diluted 1:100 in 1% milk proteins. Bound autoAbs were
revealed with biotinylated-anti-human IgG Ab (Jackson) and
developed with HRP-streptavidin. After densitometry analyses
performed with Quantity-OneH software (BioRad) for each a-, b-
and c-subunit, the mean+2 SD of the OD values for the control
sera were the threshold for positivities.
Assessment of intracellular pH and ATP synthase function
pHi was measured by flow cytometry. Briefly, EAhy926 cells
were suspended in HBSS supplemented with 0.32 mM BCECF
(Invitrogen). Cells were then incubated at 37uC to allow BCECF
to be hydrolyzed by intracellular esterase into pH-dependent
fluorescent probe and analyzed in an Epics XL flow cytometer.
Excitation at wavelength 488nm led to green and red fluores-
cences that were selected using a 525nm and a 640nm bandpass
filter, respectively. While emission intensity at 525nm is stable that
at 640nm decreases with pHi. Therefore, 525/640 nm ratio that
increases linearly with pH was considered as an appropriate tool
for the evaluation of ATP synthase activity [46]. To ascertain the
reproducibility of the method, calibration curves were constructed
for each experiment from BCECF-labelled cells suspended in
media with different pHe, and in the presence of 40 mM nigericin
(Sigma), an ionophore that exchanges K
+ and H
+ across cellular
membranes. In these conditions, pHi measured corresponds to
pHe [22].
EAhy926 cells labelled with BCECF were incubated 1:20 with
100 mL of serum, or with 50 mg/mL anti-ATP synthase mAb
(clone 4.3E8.D10, Sigma-Aldrich) for 1 h at 4uC. The cells were
then washed in medium with appropriate pHe and incubated in
the same medium for 20 minutes at 37uC before flow cytometry
analysis. Modulation of pHi was then evaluated. Positive control
was performed using BCECF-loaded cells suspended in medium
with different pHe and in the presence of 80 mM piceatannol
(Sigma), a tetrahydroxystilbene that inhibits specifically ATP
synthase [23].
In some experiments, sera were pre-depleted of their anti-ATP
synthase reactivity by overnight incubation at 4uC in ATP
synthase-coated microplates. Finally, in some experiments, 5.10
6
BCECF-loaded EC were incubated with 8 mg recombinant hsp60
at 80 mg/ml, before suspension with diluted sera.
Statistical analysis
All data were expressed as the mean6SD. Statistical analysis
used chi-square or Fisher’s exact test for comparisons of
percentages. Mean quantitative values were compared using the
Wilcoxon or Mann and Whitney U-test. Significance was assessed
at p=0.05.
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